MODELLING LIVING SYSTEMS PROGRESSES VERY FAST !
But, classical "Systems Biology" does not deliver. 
So why does Bio-Modeling Systems accept to be paid on a result basis?

Released by Bio-Modeling Systems: http://www.bmsystems.net/

PARIS March 29, 2005:  Bio-Modeling Systems published its second in-silico model "Model of Therapeutic Resistance to Tamoxifen" in the Journal of Molecular Endocrinology.                                                                                                                       
                                                                         
We are pleased to inform you that the complete text of our latest publication: "Model of Therapeutic Resistance to Tamoxifen" in the Journal of Molecular Endocrinology, has just been issued and is also available on our website.

You will notice that, in addition to our Integrative approach, we used for the second time a "differential gene identification technology", invented by Dr François Iris, to reveal differential gene expression patterns without recourse to the classical methods that only allow to either indulge in wild guesses or find what one already knows.

Bio-Modeling Systems will be present at BioSquare 2005 in Lyon. In the mean time, we invite you to download our new presentation and our latest model publication from our website: http://www.bmsystems.net/

About the Company:
 Our company is the first “Systems Biology” company that does NOT sell its technologies NOR access to its technologies, but sells solutions to Pharma and accepts to be paid on results. We find and validate new therapeutic/pathological/side effects mechanisms, and new therapeutic approaches from client's existing drug and target portfolios.

Bio-Modeling Systems is the only independent integrative Systems biology company that:

Ø	Has already produced ten semi-quantitative in-silico integrated physiological models of complex human pathologies.
Ø	Has already independently experimentally validated four of them.
•	Has already published two in peer reviewed scientific journals: Nucleic Acids Research (Oxford university publication) and the Journal of Molecular Endocrinology.
•	Is preparing publication of another two.
Ø	Accepts to be paid on results and to share business risks with its clients and,
Ø	Is currently contractually collaborating with Big Pharma in major domains of drugs and targets therapeutic applications.

Bio-Modeling Systems was incorporated in 2004 and is fully owned by its founders

Looking forward meeting you again in the near future,

Best regards,

Manuel GEA 
Co-founder and CEO
BIO-MODELING SYSTEMS
Integrative Systems Biology
26 rue Saint Lambert
75015 PARIS FRANCE
mobile: +33 (0)6 83 06 12 72
email: mailto:manuel.gea@bmsystems.net
web: www.bmsystems.net